124-94-7 Usage
Uses
Used in Pharmaceutical Industry:
Triamcinolone is used as an antiasthmatic (inhalant) for the treatment of asthma. It helps to reduce inflammation and constriction in the airways, improving breathing for patients with asthma.
Triamcinolone is also used as an antiallergic (nasal) to treat allergic rhinitis. It helps to alleviate symptoms such as sneezing, itching, and nasal congestion by reducing inflammation in the nasal passages.
In addition to its use in the pharmaceutical industry, Triamcinolone has potential applications in other areas, such as dermatology, where it can be used in the form of its 16,17-acetonide to treat various skin infections.
Originator
Kenacort,Squibb,US,1958
Indications
Intralesional bleomycin, a cytotoxic drug that inhibits DNA synthesis, is effective
for all varieties of recalcitrant warts. Various concentrations of the drug have
been used, although the total dose must be carefully tracked over time to avoid
potential systemic toxicity.
Manufacturing Process
Preparation of δ1,4-Pregnandiene-9α-fluoro-11β,16α,17α,21-Tetrol-16,21-
Diacetate: An agar slant of Corynebacterium simplex was washed with 5 ml of
sterile saline and the spore suspension added to 100 ml of Trypticase soy
broth in a 500 ml Erlenmeyer. The mixture was incubated at 32°C for 8 hr and
1 ml was used to inoculate 10 flasks, each containing 100 ml of Trypticase soy
broth. The flasks were incubated with shaking at 32°C for 16 hr. 20 mg δ4-
pregnene-9α-fluoro-11β,16α,17α,21-tetrol-3,20-dione16,21-diacetate
dissolved in 2 ml ethanol was added and the flasks pooled. This solution was
extracted several times with methylene chloride, washed with saturated saline
and evaporated under reduced pressure. The residue was dissolved in
methanol, treated with activated charcoal, filtered through diatomaceous earth
and reevaporated to afford 277 mg of oil and acetylated overnight.
Paper strip chromatography showed approximately equal amounts of substrate
and a more polar product (δ1,4-pregnadiene-9α-fluoro-11β,16α,17α,21-tetrol-
3,20-dione 16,21-diacetate) together with very small amounts of two less
polar products. Partition chromatography of 0.25 gram of the residue
(diatomaceous earth column; system: 2 parts ethyl acetate, 3 parts petroleum
ether (90° to 100°C), 3 parts methanol and 2 parts water) separated the less
polar products and the substrate. The desired most polar product remained on
the column and was eluted with 500 ml of methanol. The residue (90 mg)
from the evaporated methanol was repartitioned on diatomaceous earth
[system: 3 parts ethyl acetate, 2 parts petroleum ether (90° to 100°C), 3
parts methanol, and 2 parts water] and the cut containing the desired product
(determined by ultraviolet absorption spectrum) was evaporated under
reduced pressure to afford 18 mg of solid.
Crystallization from acetone-petroleum ether gave 13 mg of colorless needles
of δ1,4-pregnadiene-9α-fluoro-11β,16α,17α,21-tetrol-3,20-dione16,21-
diacetate; melting point (Kofler block) about 150° to 240°C with apparent loss
of solvent at 150°C. Recrystallization from acetone-petroleum ether did not
alter the melting point.
Preparation of δ1,4-Pregnadiene-9α-Fluoro-11β,16α,17α,21-Tetrol-3,20-Dione:
A solution of 100 mg of δ1,4-pregnadiene-9α-fluoro-11β,16α,17α,21-tetrol-
3,20-dione16,21-diacetate was dissolved in 10 ml of methanol and cooled to
0°C. After flushing with nitrogen, a solution of 35 mg of potassium hydroxide
in 2 ml of methanol was added to the steroid solution. After standing at room
temperature for 1 hour, the solution was neutralized with glacial acetic acid
and evaporated under a nitrogen atmosphere to a white solid. Water was
added, and after cooling, the product was filtered and washed with water to
afford 52 mg of δ1,4-pregnadiene-9α-fluoro-11β,16α,17α,21-tetrol-3,20-dione,
melting point 246° to 249°C. Three crystallizations from acetone-petroleum
ether gave 29 mg of the tetrol, melting point 260° to 262.5°C according to US
Patent 2,789,118.
Therapeutic Function
Glucocorticoid
Biochem/physiol Actions
Triamcinolone is a synthetic glucocorticoid agonist; induces gene expression and apoptosis; inhibits prostaglandin synthesis; impairs tumor necrosis factor (TNF)-α-induced degradation of κB-α; potentiates the differentiation-inducing effects of bone morphogenetic proteins (BMP-2, -4, -6).
Clinical Use
Triamcinolone to be used topically is generally dispensed as its more potent and lipophilic acetonide, a
16α,17α-methylenedioxy cyclic ketal or isopropylidene derivative. It is effective in the treatment of psoriasis and other corticoid-sensitive dermatologic
conditions. Topically, triamcinolone acetonide is a more potent derivative of triamcinolone and is approximately
eight times more active than prednisolone.
Side effects
Even though triamcinolone has an apparently decreased tendency to cause salt and water retention and edema
and may induce sodium and water diuresis, it causes other unwanted side effects, including anorexia, weight
loss, muscle weakness, leg cramps, nausea, dizziness, and a general toxic feeling.
Safety Profile
Poison by subcutaneous route.An experimental teratogen. Other experimentalreproductive effects. Human mutation data reported.When heated to decomposition it emits toxic fumes of F??.An anti-inflammatory and antiallergic agent.
Synthesis
Triamcinolone, 9a-fluoro-11b,16a,17,21-tetrahydroxypregna-1,
4-dien-3,20-dione (27.1.61), differs from dexamethsone in terms of chemical structure in that the a methyl group at C16 is replaced with a hydroxyl group. It is synthesized
from the 21-O-acetate of hydrocortisone 27.1.17. In the first stage, both carbonyl groups
of this compound undergo ketalization by ethylene glycol. Next, the hydroxyl group in
the resulting diketal 27.1.53 is replaced with chlorine using thionyl chloride, and
the product undergoes dehydrochlorination using an alkaline, during which the
21-O-acetyl group also is hydrolyzed. Acetylating the hydroxyl group once again
with acetic anhydride gives a triene 27.1.54. Reacting this with osmium tetroxide
gives the vicinal diol 27.1.55. The secondary hydroxyl group at C16 of this product
undergoes acetylation by acetic anhydride in pyridine, which forms the diacetate
27.1.56. Treating the product with N-bromoacetamide in chloric acid gives a bromohydrin
(27.1.57), which upon reaction with potassium acetate is transformed to an epoxide
(27.1.58). Opening of the epoxide ring, using hydrofluoric acid, gives the corresponding
9-fluoro-11-hydroxy derivative 27.1.59. Upon microbiological dehydrogenation, the
C1–C2 bond is oxidized to a double bond, forming triamcinolone acetate (27.1.60), the
acetyl group of which is hydrolyzed, forming the desired triamcinolone (27.1.61).
Drug interactions
Potentially hazardous interactions with other drugs
Aldesleukin: avoid concomitant use.
Antibacterials: metabolism accelerated by rifamycins;
metabolism possibly inhibited by erythromycin;
concentration of isoniazid possibly reduced.
Anticoagulants: efficacy of coumarins and
phenindione may be altered.
Antiepileptics: metabolism accelerated by
carbamazepine, fosphenytoin, phenobarbital,
phenytoin and primidone.
Antifungals: increased risk of hypokalaemia with
amphotericin - avoid; metabolism possibly inhibited
by itraconazole and ketoconazole.
Antivirals: concentration possibly increased by
ritonavir.
Ciclosporin: rare reports of convulsions in patients
on ciclosporin and high-dose corticosteroids.
Cobicistat: concentration of triamcinolone possibly
increased.
Diuretics: enhanced hypokalaemic effects of
acetazolamide, loop diuretics and thiazide diuretics.
Vaccines: high dose corticosteroids can impair
immune response to vaccines; avoid with live
vaccines.
Metabolism
Triamcinolone is metabolised largely hepatically but
also by the kidney and is excreted in urine. The main
metabolic route is 6-beta-hydroxylation; no significant
hydrolytic cleavage of the acetonide occurs.
Check Digit Verification of cas no
The CAS Registry Mumber 124-94-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,2 and 4 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 124-94:
(5*1)+(4*2)+(3*4)+(2*9)+(1*4)=47
47 % 10 = 7
So 124-94-7 is a valid CAS Registry Number.
InChI:InChI=1/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13?,14?,15-,16+,18+,19+,20+,21+/m1/s1
124-94-7Relevant articles and documents
Synthesis method and application of 9-fluorosteroid compound
-
Paragraph 0089-0096; 0131-0133, (2021/01/15)
The invention provides a synthesis method and application of a 9-fluorosteroid compound, and relates to the technical field of chemical synthesis. The synthesis method of the 9-fluorosteroid compoundcomprises the following step: reacting a compound II in an ionic liquid containing hydrogen fluoride salt to obtain a 9-fluorosteroid compound III. According to the synthesis method of the 9-fluorosteroid compound, the ionic liquid containing the hydrogen fluoride salt is used as a fluorinating agent to replace a traditional hydrogen fluoride aqueous solution, volatilization of hydrogen fluoride gas is avoided, corrosivity is small, toxicity is greatly reduced, reaction conditions are mild, reaction can be completed at the room temperature, operability is high, the safety coefficient is high,and production applicability is improved. The synthesis method of the 9-fluorosteroid compound is used for preparing corticosteroid drugs, highly toxic chemical reagents are not used in the synthesisroute, the operability is high, the safety coefficient is high, and the production applicability is improved.
Preparation method of triamcinolone
-
Paragraph 0047-0049, (2018/03/25)
The invention provides a brand new synthesis route for preparation of triamcinolone; adopted raw materials are cheaper and easier to obtain, reactive raw materials are hydroxylated and then protectionis performed, five-membered ring double bonds are subjected to selective oxidation, generated di-hydroxyl is subjected to esterification protection, then six-membered ring double bonds are subjectedto epoxidation and are subjected to ring-opening fluorination to remove a protective group, and thus the triamcinolone product is obtained. The reaction process is easy to operate, the yield of each step is relatively high, and the purity of the obtained product is higher, the formation of by-products is effectively avoided, the production cost is reduced and industrialized production is facilitated.
NOVEL PROCESS FOR PREPARATION OF GLUCOCORTICOID STEROIDS
-
Page/Page column 26, (2016/08/23)
The present invention discloses a process for the preparation of 16, 17-acetals of pregnane derivatives having formula (I) wherein each substituent is independently selected from; R1 is H or CH3; R2 is C1-C6 linear or branched alkyl, alkynyl group or cycloalkyl group; aryl or heteroaryl group; or R1 and R2 combine to form saturated, unsaturated C3-C6 cyclic or heterocyclic ring; R3 and R4 are same or different and each independently represents H or halogen; R5 is -OH or –OCOR wherein R represents H or C1-C6 linear, branched or cyclic alkyl group that may be substituted.
Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
-
, (2008/06/13)
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
-
, (2008/06/13)
Mucosal adhesive devices are provided for use in the oral cavity for therapy against infections. The devices are dosage units which comprise a combination of antimicrobial agents such as antifungal agents and anti-inflammatory agents, optionally also a local anesthetic. The dosage units yield a gradual and relatively constant release of the pharmaceuticals over at least a 12-hour period.
High molecular weight prodrug derivatives of antiinflammatory drugs
-
, (2008/06/13)
Compounds of the formula 1, PS - O - A - (CH2)n- B - D (1), wherein PS-O represents an alkoxide residue of any of the free hydroxy groups of a polysaccharide (PS-OH) compound with molecular weight (Mw) of from 40,000 to 5,000,000 selected from dextran, carboxymethyl dextran, diethylaminoethyl dextran, starch, hydroxyet-hyl starch, alginates, glycogen, pullullan, agarose, cellulose, chitosan, chitin and carrageenan,A is a carbonyl group or absent,n is zero or a positive integer from 1 to 14,B is oxygen, a carbonyl group, NR wherein R is hydrogen or lower alkyl, or B is absent, and, D is (i) a group of the formula:, R1 - CO - (11), wherein R1-CO- represents the acyl residue of a carboxylic acid drug (R1-COOH) used in the treatment of inflammatory disorders; or (ii) a group of the formula:, R2 - O - (12), wherein R2-O- refers to the C-21 alkoxide residue of a known antiinflammatory steroid (R2-OH) or an alkoxide residue of any other drug or medicament containing a hydroxy functional group used in the treatment of inflammatory disorders; with the proviso that when A is absent, n is 0, and B is absent, then R1-CO- is different from the acyl residue of acetylsalicylic acid;, and non-toxic pharmaceutically acceptable acid addition salts thereof;, and non-toxic pharmaceutically acceptable cation salts thereof. Such compounds are biolabile prodrugs providing controlled release and prolonged duration of action of the parent active antiinflamma-tory agents locally at the administration site after intra-articular, intra-muscular, subcutaneous or extra-dural application while at the same time being highly stable in aqueous solution in the pH range 3--5. After oral administration of such prodrugs the parent drug is liberated selectively in the terminal ileum and the colon over an extended period of time.
Process for preparing salt of hyaluronic acid with a pharmaceutically active substance
-
, (2008/06/13)
Pharmaceutical preparations for topical administration containing a pharmacologically active substance together with hyaluronic acid or a molecular weight fraction thereof. The hyaluronic acid may be in the form of the free acid or may be a salt with an alkali or alkaline earth metal, magnesium, aluminum or ammonium, or in the form of a salt with one or more pharmacologically active substances.
Amine containing ester prodrugs of corticosteroids
-
, (2008/06/13)
Novel solution stable ester prodrugs of corticosteroids of the formula STR1
Amine containing ester prodrugs of corticosteroids
-
, (2008/06/13)
Novel solution stable ester prodrugs of corticosteroids of the formula STR1
Sulfonate containing ester prodrugs of corticosteroids
-
, (2008/06/13)
Novel solution stable ester prodrugs of corticosteroids of the formula STR1 and their salts.
